Small cell lung cancer: Can recent advances in biology and molecular biology be translated into improved outcomes?

Journal of Thoracic Oncology

Volumn 11, Issue 4, 2016, Pages 453-474

  Bunn, Paul A ^a   Minna, John D ^b   Augustyn, Alexander ^b   Gazdar, Adi F ^b   Ouadah, Youcef ^c   Krasnow, Mark A ^c   Berns, Anton ^d   Brambilla, Elisabeth ^e   Rekhtman, Natasha ^f   Massion, Pierre P ^g   Niederst, Matthew ^h   Peifer, Martin ⁱ   Yokota, Jun ^j,k   Govindan, Ramaswamy ^l   Poirier, John T ^f   Byers, Lauren A ^m   Wynes, Murry W ⁿ   McFadden, David G ^b   MacPherson, David ^o   Hann, Christine L ^p   Farago, Anna F ^h   Dive, Caroline ^q   Teicher, Beverly A ^r   Peacock, Craig D ^s   Johnson, Jane E ^b   Cobb, Melanie H ^b   Wendel, Hans Guido ^f   Spigel, David ^t   Sage, Julien ^c   Yang, Ping ^u   Pietanza, M Catherine ^f   Krug, Lee M ^f   Heymach, John ^m   Ujhazy, Peter ^u   Zhou, Caicun ^v   Goto, Koichi ^w   Dowlati, Afshin ^x   Christensen, Camilla Laulund ^y   Park, Keunchil ^z   Einhorn, Lawrence H ^aa   Edelman, Martin J ^ab   Giaccone, Giuseppe ^ac   Gerber, David E ^b   Salgia, Ravi ^ad   Owonikoko, Taofeek ^ae   Malik, Shakun ^r   Karachaliou, Niki ^af   Gandara, David R ^ag   Slotman, Ben J ^ah   Blackhall, Fiona ^ai   Goss, Glenwood ^aj   Thomas, Roman ⁱ   Rudin, Charles M ^f   Hirsch, Fred R ^a   more..

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY   (United States)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e GRENOBLE UNIVERSITY HOSPITAL   (France)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g VANDERBILT UNIVERSITY   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ UNIVERSITY OF COLOGNE   (Germany)

^j Institute of Predictive and Personalized Medicine of Cancer   (Spain)

^k NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^l WASHINGTON UNIVERSITY   (United States)

^m UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁿ International Association for the Study of Lung Cancer   (United States)

^o Fred Hutchinson Cancer Research Center   (United States)

^p JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^q UNIVERSITY OF MANCHESTER   (United Kingdom)

^r NATIONAL CANCER INSTITUTE   (United States)

^s LERNER RESEARCH INSTITUTE   (United States)

^t Sara Cannon Research Institute   (United States)

^u MAYO CLINIC CANCER CENTER   (United States)

^v TONGJI UNIVERSITY   (China)

^w NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^x UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^y DANA FARBER CANCER INSTITUTE   (United States)

^z Sungkyunkwan University School of Medicine   (South Korea)

^aa INDIANA UNIVERSITY   (United States)

^ab UNIVERSITY OF MARYLAND   (United States)

^ac GEORGETOWN UNIVERSITY   (United States)

^ad UNIVERSITY OF CHICAGO   (United States)

^ae EMORY UNIVERSITY   (United States)

^af INSTITUT UNIVERSITARI DEXEUS   (Spain)

^ag UNIVERSITY OF CALIFORNIA   (United States)

^ah VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^ai UNIVERSITY OF MANCHESTER   (United Kingdom)

^aj UNIVERSITY OF OTTAWA   (Canada)

more..

Author keywords

Gene mutations; Immunotherapy; Neuroendocrine; Small cell lung cancer; Therapy

Indexed keywords

2 ALLYL 1 [6 (1 HYDROXY 1 METHYLETHYL) 2 PYRIDINYL] 6 [4 (4 METHYL 1 PIPERAZINYL)ANILINO] 1H PYRAZOLO[3,4 D]PYRIMIDIN 3(2H) ONE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ALISERTIB; AMRUBICIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AURORA KINASE INHIBITOR; BARASERTIB; CD47 ANTIGEN; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CHIMERIC ANTIGEN RECEPTOR; DRUG ANTIBODY; FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR; FOCAL ADHESION KINASE INHIBITOR; GANGLIOSIDE; INITIATION FACTOR 4E INHIBITOR; JANUS KINASE INHIBITOR; NAVITOCLAX; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NOTCH RECEPTOR INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLATINUM; PROTEIN RET INHIBITOR; PROTEOME; RADIOISOTOPE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EZH2 INHIBITOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER THERAPY; CARCINOGENESIS; DEVELOPED COUNTRY; DRUG CONJUGATION; DRUG TARGETING; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENOME; HUMAN; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG ADENOCARCINOMA; LUNG CARCINOID; MOLECULAR BIOLOGY; NEUROENDOCRINE TUMOR; NEUROSECRETORY CELL; NONHUMAN; ONCOGENE; PIK3CA GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SMALL CELL LUNG CANCER; UNITED STATES; ANIMAL; GENETICS; IMMUNOLOGY; LUNG NEOPLASMS; SMALL CELL LUNG CARCINOMA;

ANIMALS; HUMANS; LUNG NEOPLASMS; MOLECULAR BIOLOGY; SMALL CELL LUNG CARCINOMA;

EID: 84962812153     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.01.012     Document Type: Review

References (165)

1. Arcaro A. Targeted therapies for small cell lung cancer: Where do we stand? Crit Rev Oncol Hematol. 2015;95:154-164.
2. Byers LA, Rudin CM. Small cell lung cancer: where do we go from here? Cancer. 2015;121:664-672.
3. Ardizzoni A, Hansen H, Dombernowsky P, et al. Top-otecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol. 1997;15:2090-2096.
4. George J, Lim JS, Jang SJ, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524:47-53.
5. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24:4539-4544.
6. Visvader JE. Cells of origin in cancer. Nature. 2011;469: 314-322.
7. Rowbotham SP, Kim CF. Diverse cells at the origin of lung adenocarcinoma. Proc Natl Acad Sci U S A. 2014;111:4745-4746.
8. Logan CY, Desai TJ. Keeping it together: pulmonary alveoli are maintained by a hierarchy of cellular programs. Bioessays. 2015;37:1028-1037.
9. Sutherland KD, Proost N, Brouns I, et al. Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell. 2011;19:754-764.
10. Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543-550.
11. Desai TJ, Brownfield DG, Krasnow MA. Alveolar progenitor and stem cells in lung development, renewal and cancer. Nature. 2014;507:190-194.
12. Meuwissen R, Linn SC, Linnoila RI, et al. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell. 2003;4:181-189.
13. Rad R, Rad L, Wang W, et al. PiggyBac transposon mutagenesis: a tool for cancer gene discovery in mice. Science. 2010;330:1104-1107.
14. Crapo JD, Barry BE, Gehr P, et al. Cell number and cell characteristics of the normal human lung. Am Rev Respir Dis. 1982;126:332-337.
15. Gosney JR. Neuroendocrine cell populations in postnatal human lungs: minimal variation from childhood to old age. Anat Rec. 1993;236:177-180.
16. Niederst MJ, Sequist LV, Poirier JT, et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun. 2015;6:6377.
17. Semenova EA, Nagel R, Berns A. Origins, genetic landscape, and emerging therapies of small cell lung cancer. Genes Dev. 2015;29:1447-1462.
18. Sequist LV, Waltman BA, Dias-Santagata D, et al. Geno-typic and histological evolution oflung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3: 75ra26.
19. Calbo J, van Montfort E, Proost N, et al. A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. Cancer Cell. 2011;19:244-256.
20. Kuo CS, Krasnow MA. Formation of a neurosensory organ by epithelial cell slithering. Cell. 2015;163:394-405.
21. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG, eds. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 4th ed. Lyon, France: IARC Press; 2015.
22. Debelenko LV, Brambilla E, Agarwal SK, et al. Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. Hum Mol Genet. 1997;6:2285-2290.
23. Fernandez-Cuesta L, Peifer M, Lu X, et al. Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nat Commun. 2014;5:3518.
24. Asamura H, Kameya T, Matsuno Y, et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol. 2006;24:70-76.
25. Rekhtman N. Neuroendocrine tumors of the lung: an update. Arch Pathol Lab Med. 2010;134:1628-1638.
26. Jones MH, Virtanen C, Honjoh D, et al. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet. 2004;363:775-781.
27. Le Treut J, Sault MC, Lena H, et al. Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study. Ann Oncol. 2013;24:1548-1552.
28. Rossi G, Cavazza A, Marchioni A, et al. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol. 2005;23:8774-8785.
29. Rekhtman N, Pietanza MC, Hellmann MD, et al. Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinomalike andnon-smallcell carcinoma-likesubsets.ClinCancer Res, in press.
30. Peifer M, Fernandez-Cuesta L, Sos ML, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012;44:1104-1110.
31. Rudin CM, Durinck S, Stawiski EW, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet. 2012;44:1111-1116.
32. Yokomizo A, Tindall DJ, Drabkin H, et al. PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers. Oncogene. 1998;17:475-479.
33. Nau MM, Brooks BJ, Battey J, et al. L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. Nature. 1985;318:69-73.
34. Iwakawa R, Takenaka M, Kohno T, et al. Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer. Genes Chromosomes Cancer. 2013;52:802-816.
35. Sun JM, Choi YL, Ji JH, et al. Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing. Ann Oncol. 2015;26:161-166.
36. Varghese AM, Zakowski MF, Yu HA, et al. Small-cell lung cancers in patients who never smoked cigarettes. J Thorac Oncol. 2014;9:892-896.
37. Poirier JT, Dobromilskaya I, Moriarty WF, et al. Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer.JNatl Cancer Inst. 2013;105:1059-1065.
38. Poirier JT, Gardner EE, Connis N, et al. DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2. Oncogene. 2015;34:5869-5878.
39. Kim W, Bird GH, Neff T, et al. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat Chem Biol. 2013;9:643-650.
40. Wee ZN, Li Z, Lee PL, et al. EZH2-mediated inactivation of IFN-gamma-JAK-STAT1 signaling is an effective therapeutic target in MYC-driven prostate cancer. Cell Rep. 2014;8:204-216.
41. Byers LA, Wang J, Nilsson MB, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012;2:798-811.
42. Wainberg ZA, Rafii S, Ramanathan RK, et al. Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients [abstract] ASCO Meeting Abstracts. 2014;32: 7522.
43. Cardnell RJ, Feng Y, Diao L, et al. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin Cancer Res. 2013;19:6322-6328.
44. Valliani AA, Sen T, Masrorpour F, et al. Abstract 5316: Check point kinase 1 (Chk1) targeting as a novel therapeutic strategy in small cell lung cancer (SCLC). Cancer Res. 2015;75:5316.
45. Pietanza MC, Byers LA, Minna JD, et al. Small cell lung cancer: will recent progress lead to improved outcomes? Clin Cancer Res. 2015;21:2244-2255.
46. Gazdar AF, Savage TK, Johnson JE, et al. The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung. J Thorac Oncol. 2015;10:553-564.
47. Calbo J, Meuwissen R, van Montfort E, et al. Genotype-phenotype relationships in a mouse model for human small-cell lung cancer. Cold Spring Harb Symp Quant Biol. 2005;70:225-232.
48. Dooley AL, Winslow MM, Chiang DY, et al. Nuclear factor I/B is an oncogene in small cell lung cancer. Genes Dev. 2011;25:1470-1475.
49. McFadden DG, Papagiannakopoulos T, Taylor-Weiner A, et al. Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. Cell. 2014;156:1298-1311.
50. Cui M, Augert A, Rongione M, et al. PTEN is a potent suppressor of small cell lung cancer. Mol Cancer Res. 2014;12:654-659.
51. Song H, Yao E, Lin C, et al. Functional characterization of pulmonary neuroendocrine cells in lung development, injury, and tumorigenesis. Proc Natl Acad Sci U S A. 2012;109:17531-17536.
52. Gilbert LA, Hemann MT. DNA damage-mediated induction of a chemoresistant niche. Cell. 2010;143:355-366.
53. Huijbers IJ, Bin Ali R, Pritchard C, et al. Rapid target gene validation in complex cancer mouse models using re-derived embryonic stem cells. EMBO Mol Med. 2014;6:212-225.
54. Hou JM, Krebs MG, Lancashire L, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol. 2012;30:525-532.
55. Hodgkinson CL, Morrow CJ, Li Y, et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med. 2014;20:897-903.
56. Park KS, Martelotto LG, Peifer M, et al. A crucial requirement for hedgehog signaling in small cell lung cancer. Nat Med. 2011;17:1504-1508.
57. Belani CP, Dahlberg SE, Rudin CM, et al. Three-arm randomized phase II study of cisplatin and etoposide (CE) versus CE with either vismodegib (V) or cix-utumumab (Cx) for patients with extensive stage-small cell lung cancer (ES-SCLC) (ECOG 1508) [abstract] J Clin Oncol. 2013;31(suppl):7508.
58. Tai D, Wells K, Arcaroli J, et al. Targeting the WNT signaling pathway in cancer therapeutics. Oncologist. 2015;20:1189-1198.
59. Augustyn A, Borromeo M, Wang T, et al. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. Proc Natl Acad Sci U S A. 2014;111:14788-14793.
60. Osborne JK, Larsen JE, Gonzales JX, et al. NeuroD1 regulation of migration accompanies the differential sensitivity of neuroendocrine carcinomas to TrkB inhibition. Oncogenesis. 2013;2:e63.
61. Osborne JK, Larsen JE, Shields MD, et al. NeuroD1 regulates survival and migration of neuroendocrine lung carcinomas via signaling molecules TrkB and NCAM. Proc Natl Acad Sci U S A. 2013;110:6524-6529.
62. Ben-Ezra JM, Kornstein MJ, Grimes MM, et al. Small cell carcinomas of the lung express the Bcl-2 protein. Am J Pathol. 1994;145:1036-1040.
63. Ikegaki N, Katsumata M, Minna J, et al. Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res. 1994;54:6-8.
64. Jiang SX, Sato Y, Kuwao S, et al. Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J Pathol. 1995;177:135-138.
65. Hann CL, Daniel VC, Sugar EA, et al. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res. 2008;68:2321-2328.
66. Garnett MJ, Edelman EJ, Heidorn SJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012;483:570-575.
67. Faber AC, Farago AF, Costa C, et al. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. Proc Natl Acad Sci U S A. 2015;112:E1288-E1296.
68. Rudin CM, Hann CL, Garon EB, et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res. 2012;18:3163-3169.
69. Gardner EE, Connis N, Poirier JT, et al. Rapamycin rescues ABT-737 efficacy in small cell lung cancer. Cancer Res. 2014;74:2846-2856.
70. Wendel HG, Silva RL, Malina A, et al. Dissecting eIF4E action in tumorigenesis. Genes Dev. 2007;21:3232-3237.
71. Wolfe AL, Singh K, Zhong Y, et al. RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer. Nature. 2014;513:65-70.
72. Hayama S, Daigo Y, Yamabuki T, et al. Phosphorylation and activation of cell division cycle associated 8 by aurora kinase B plays a significant role in human lung carcinogenesis. Cancer Res. 2007;67:4113-4122.
73. Vischioni B, Oudejans JJ, Vos W, et al. Frequent over-expression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients. Mol Cancer Ther. 2006;5:2905-2913.
74. Sos ML, Dietlein F, Peifer M, et al. A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proc Natl Acad SciU S A. 2012;109:17034-17039.
75. Helfrich B, Kim J, Gao D, et al. The Aurora Kinase B Inhibitor AZD1152-HQPA Inhibitor in Small Cell Lung Cancer (SCLC). J Thorac Oncol. 2015;10:S363.
76. Melichar B, Adenis A, Lockhart AC, et al. Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study. Lancet Oncol. 2015;16:395-405.
77. Jenkins DW, Ross S, Veldman-Jones M, et al. MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo. Mol Cancer Ther. 2012;11:1650-1660.
78. Ingram I. Tarextumab gets FDA orphan drug designation for lung, pancreatic cancer. http://www.cancernetwork. com/news/tarextumab-fda-orphan-drug-lung-pancreatic-cancer. Accessed December 28, 2015.
79. Smith DC, Eisenberg PD, Manikhas G, et al. A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors. Clin Cancer Res. 2014;20:6295-6303.
80. Schultheis AM, Bos M, Schmitz K, et al. Fibroblast growth factor receptor 1 (FGFR1) amplification is a potential therapeutic target in small-cell lung cancer. Mod Pathol. 2014;27:214-221.
81. Wynes MW, Hinz TK, Gao D, et al. FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. Clin Cancer Res. 2014;20:3299-3309.
82. Soria JC, DeBraud F, Bahleda R, et al. Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. Ann Oncol. 2014;25:2244-2251.
83. Umemura S, Mimaki S, Makinoshima H, et al. Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis. J Thorac Oncol. 2014;9:1324-1331.
84. Kolev VN, Xu Q, Pachter JA, et al. FAK and PI3K/mTOR inhibitors target cancer stem cells: implications for SCLC treatment strategies [abstract]. In Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, April 18-22, 2015. Philadelphia, PA: AACR; 1525.
85. Dabir S, Babakoohi S, Kluge A, et al. RET mutation and expression in small-cell lung cancer. J Thorac Oncol. 2014;9:1316-1323.
86. Loven J, Hoke HA, Lin CY, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013;153:320-334.
87. Junttila MR, de Sauvage FJ. Influence of tumour microenvironment heterogeneity on therapeutic response. Nature. 2013;501:346-354.
88. Yu H, Lee H, Herrmann A, et al. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014;14:736-746.
89. Curtis JR, Lee EB, Kaplan IV, et al. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme [e-pub ahead of print]. Ann Rheum Dis. http://dx.doi.org/10.1136/annrheumdis-2014-205847. Accessed December 22, 2015.
90. Looyenga BD, Hutchings D, Cherni I, et al. STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma. PLoS One. 2012;7:e30820.
91. Lee JH, Park KS, Alberobello AT, et al. The Janus kinases inhibitor AZD1480 attenuates growth of small cell lung cancers in vitro and in vivo. Clin Cancer Res. 2013;19: 6777-6786.
92. Ettinger DS, Jotte R, Lorigan P, et al. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol. 2010;28:2598-2603.
93. Onoda S, Masuda N, Seto T, et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol. 2006;24:5448-5453.
94. von Pawel J, Jotte R, Spigel DR, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol. 2014;32:4012-4019.
95. Mita MM, Natale RB, Wolin EM, et al. Pharmacokinetic study of aldoxorubicin in patients with solid tumors. Invest New Drugs. 2015;33:341-348.
96. Lara PN, Jr., Moon J, Redman MW, et al. Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials. J Thorac Oncol. 2015;10:110-115.
97. Luo M, Fan H, Nagy T, et al. Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. Cancer Res. 2009;69: 466-474.
98. Sullivan B. Verastem stops enrollment due to futility in the COMMAND Study of VS-6063 for the Treatment of Malignant Pleural Mesothelioma-no difference in VS-6063 versus placebo in either the intent to treat population or patients with Merlin-low tumors. http://www.businesswire.com/news/home/20150928005465/en/Verastem-Stops-Enrollment-Due-Futility-COMMAND-Study. Accessed December 23, 2015.
99. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol. 2004;14:171-179.
100. Kucia M, Reca R, Miekus K, et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells. 2005;23:879-894.
101. Otsuka S, Bebb G. The CXCR4/SDF-1 chemokine receptor axis: a new target therapeutic for non-small cell lung cancer. J Thorac Oncol. 2008;3:1379-1383.
102. Reckamp KL, Figlin RA, Burdick MD, et al. CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer. BMC Cancer. 2009;9:213.
103. Spigel DR, Weaver RW, McCleod M, et al. Phase II study of carboplatin/etoposide plus LY2510924, a CXCR4 peptide antagonist, versus carboplatin/etoposide in patients with extensive-stage small cell lung cancer (SCLC). Ann Oncol. 2014;25:iv514.
104. Rouleau M, Patel A, Hendzel MJ, et al. PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010;10:293-301.
105. Owonikoko TK, Zhang G, Deng X, et al. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. Cancer Med. 2014;3:1579-1594.
106. ISRCTNRegistry. STOMP: Small cell lung cancer Trial of Olaparib (AZD2281) as Maintenance Programme. http://www.isrctn.com/ISRCTN73164486. Accessed December 28, 2015.
107. Owonikoko TK, Dahlberg SE, Khan SA, et al. A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E2511). Lung Cancer. 2015;89:66-70.
108. Pietanza MC, Kadota K, Huberman K, et al. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. Clin Cancer Res. 2012;18:1138-1145.
109. Bouchard H, Viskov C, Garcia-Echeverria C. Antibody-drug conjugates-a new wave of cancer drugs. Bioorg Med Chem Lett. 2014;24:5357-5363.
110. Whiteman KR, Johnson HA, Mayo MF, et al. Lorvotuzu-mab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models. MAbs. 2014;6:556-566.
111. Spigel DR, Bendell J, Mita AC, et al. Phase I/II study to assess the safety, pharmacokinetics (PK) and efficacy of lorvotuzumab mertansine (LM, IMGN901) in combination with carboplatin/etoposide in patients with solid tumors including small-cell lung cancer (SCLC). Ann Oncol. 2012;23:ix498.
112. Saunders LR, Bankovich AJ, Anderson WC, et al. A DLL3-targeted antibody-drug conjugate eradicates highgrade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med. 2015;7:302ra136.
113. Rudin CM, Pietanza MC, Spigel DR, et al. A DLL3-Targeted ADC, Rovalpituzumab Tesirine, Demonstrates Substantial Activity in a Phase I Study in Relapsed and Refractory SCLC. J Thorac Oncol. 2015;10: S192-S193.
114. Edelman MJ, Clamon G, Kahn D, et al. Targeted radio-pharmaceutical therapy for advanced lung cancer: phase I trial of rhenium Re188 P2045, a somatostatin analog. J Thorac Oncol. 2009;4:1550-1554.
115. Romero OA, Torres-Diz M, Pros E, et al. MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1. Cancer Discov. 2014;4:292-303.
116. Fillmore CM, Xu C, Desai PT, et al. EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors. Nature. 2015;520:239-242.
117. Gitlitz BJ, Moon J, Glisson BS, et al. Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial. J Thorac Oncol. 2010;5: 1835-1840.
118. Horn L, Dahlberg SE, Sandler AB, et al. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol. 2009;27:6006-6011.
119. Lee SM, Woll PJ, Rudd R, et al. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst. 2009;101: 1049-1057.
120. Pujol JL, Breton JL, Gervais R, et al. Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. J Clin Oncol. 2007;25: 3945 3951.
121. Ready NE, Dudek AZ, Pang HH, et al. Cisplatin, irino-tecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. J Clin Oncol. 2011;29:4436-4441.
122. Ramalingam SS, Belani CP, Mack PC, et al. Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). J Thorac Oncol. 2010;5:1279 1284.
123. Arnold AM, Seymour L, Smylie M, et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol. 2007;25:4278 4284.
124. Allen JW, Moon J, Redman M, et al. Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol. 2014;32:2463-2470.
125. Abdelraouf F, Smit E, Hasan B, et al. Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: a single-arm phase II study (EORTC-08061). Eur J Cancer. 2016;54:35 39.
126. Ready NE, Pang HH, Gu L, et al. Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer: A randomized, double-blind, placebo-controlled phase II study-CALGB 30504 (Alliance). J Clin Oncol. 2015;33:1660-1665.
127. Schneider BJ, Kalemkerian GP, Ramnath N, et al. Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer. Clin Lung Cancer. 2010;11:223 227.
128. Spigel DR, Hainsworth JD, Simons L, et al. Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. J Thorac Oncol. 2007;2:854 861.
129. Maulik G, Kijima T, Ma PC, et al. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res. 2002;8:620-627.
130. Martinez P, Sales Fidalgo PA, Felip E. Ganitumab for the treatment of small-cell lung cancer. Expert Opin Investig Drugs. 2014;23:1423-1432.
131. Owonikoko TK, Stoller RG, Petro D, et al. Phase II study of RAD001 (Everolimus) in previously treated small cell lung cancer (SCLC) [abstract]. ASCO Meeting Abstracts. 2008;26:19017.
132. Tarhini A, Kotsakis A, Gooding W, et al. Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin Cancer Res. 2010;16:5900-5907.
133. Pandya KJ, Dahlberg S, Hidalgo M, et al. A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). J Thorac Oncol. 2007;2: 1036-1041.
134. Do K, Wilsker D, Ji J, et al. Phase I study of single-agent AZD1775 (MK-1775), a Wee1 kinase inhibitor, in patients with refractory solid tumors. J Clin Oncol. 2015;33:3409-3415.
135. Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015;385:36-42.
136. Antonia SJ, Mirza N, Fricke I, et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res. 2006;12:878-887.
137. Grant SC, Kris MG, Houghton AN, et al. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin. Clin Cancer Res. 1999;5: 1319-1323.
138. Ohwada A, Nagaoka I, Takahashi F, et al. DNA vaccination against HuD antigen elicits antitumor activity in a small-cell lung cancer murine model. Am J Respir Cell Mol Biol. 1999;21:37-43.
139. Smith A, Waibel R, Stahel RA. Selective immunotherapy of small cell cancer xenografts using 131I-labelled SWA11 antibody. Br J Cancer. 1991;64:263-266.
140. Zhang S, Cordon-Cardo C, Zhang HS, et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int J Cancer. 1997;73:42-49.
141. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348:56-61.
142. Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med. 2003;349: 1543-1554.
143. Roberts WK, Deluca IJ, Thomas A, et al. Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8θ T cells. J Clin Invest. 2009;119:2042-2051.
144. Graus F, Dalmou J, Rene R, et al. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol. 1997;15:2866-2872.
145. Koyama K, Kagamu H, Miura S, et al. Reciprocal CD4θ T-cell balance of effector CD62Llow CD4θ and CD62LhighCD25θ CD4θ regulatory T cells in small cell lung cancer reflects disease stage. Clin Cancer Res. 2008;14:6770-6779.
146. Doyle A, Martin WJ, Funa K, et al. Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. J Exp Med. 1985;161:1135-1151.
147. Wang W, Hodkinson P, McLaren F, et al. Small cell lung cancer tumour cells induce regulatory T lymphocytes, and patient survival correlates negatively with FOXP3θ cells in tumour infiltrate. Int J Cancer. 2012;131:E928-E937.
148. Xie D, Marks R, Zhang M, et al. Nomograms predict overall survival for patients with small-cell lung cancer incorporating pretreatment peripheral blood markers. J Thorac Oncol. 2015;10:1213-1220.
149. Horta ES, Lennon VA, Lachance DH, et al. Neural autoantibody clusters aid diagnosis of cancer. Clin Cancer Res. 2014;20:3862-3869.
150. Brahmer JR, Pardoll DM. Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer. Cancer Immunol Res. 2013;1:85-91.
151. Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, doubleblind, multicenter phase 2 trial. Ann Oncol. 2013;24: 75-83.
152. Antonia SJ, Bendell JC, Taylor MH, et al. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032 [abstract]. ASCO Meeting Abstracts. 2015;33:7503.
153. Ott PA, Fernandez MEE, Hiret S, et al. Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): preliminary safety and efficacy results from KEYNOTE-028 [abstract]. ASCO Meeting Abstracts. 2015;33:7502.
154. Ishii H, Azuma K, Kawahara A, et al. Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer. J Thorac Oncol. 2015;10:426-430.
155. Brezicka FT, Olling S, Nilsson O, et al. Immunohisto-logical detection of fucosyl-GM1 ganglioside in human lung cancer and normal tissues with monoclonal antibodies. Cancer Res. 1989;49:1300-1305.
156. Dickler MN, Ragupathi G, Liu NX, et al. Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer. Clin Cancer Res. 1999;5:2773-2779.
157. Krug LM, Ragupathi G, Hood C, et al. Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocya-nin. Clin Cancer Res. 2004;10:6094-6100.
158. Giaccone G, Debruyne C, Felip E, et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol. 2005;23: 6854-6864.
159. Levine BL. Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells. Cancer Gene Ther. 2015;22:79-84.
160. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348:62-68.
161. Jaiswal S, Jamieson CH, Pang WW, et al. CD47 is upre-gulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138: 271-285.
162. Majeti R, Chao MP, Alizadeh AA, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138:286-299.
163. Willingham SB, Volkmer JP, Gentles AJ, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A. 2012;109:6662-6667.
164. Weiskopf K, Ring AM, Ho CC, et al. Engineered SIRP-alpha variants as immunotherapeutic adjuvants to anticancer antibodies. Science. 2013;341:88-91.
165. Liu X, Pu Y, Cron K, et al. CD47 blockade triggers Tcell-mediated destruction of immunogenic tumors. Nat Med. 2015;21:1209-1215.